


# Dx&Vx

## IR Letter

(July 2024)



# Dx&Vx Business Roadmap



## Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

Genomic Diagnostics
In Vitro Diagnostics and CDMO
Genomics CRO
Companion Diagnostic Services (CliDex)



## Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

Microbiome-based Therapeutic Adjuncts
Nutrition Products
Domestic and International CSO
Functional Skincare/Personal Hygiene Products



## Drug Development

Our affiliate, Oxford Vacmedix, is preparing to initiate phase 1b clinical trials both domestically and internationally for its cancer vaccine, OVM-200, and our subsidiary Avixgen is about to start phase 2 trials for a dry eye treatment. Additionally, we have a pipeline of in-house developed drugs including microbiome-based therapies, mRNA cancer vaccines, oncology antibodies, and oral obesity treatments.

Microbiome-based Drug Development
ROP and mRNA Cancer Vaccines
Cancer Antibody Drugs, Synthetic Organic Drugs
Ophthalmic Disease Treatment Drugs







## Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

K-hub
Telemedicine Services
AI-based Drug Development Platform
Smart Diagnostic Devices

## Performance Summary for June 2024

-  Contract signed for supplying 'GenomeCheck' to the Mongolian and Malaysian markets
-  Launching 'Omic-Check Microbiome Healthcare Service'
-  \$4 Million Export Contract for 'Ofmom' Brand in Vietnam
-  Excellent preclinical trial results confirmed for oral obesity treatment candidate



### Medical Diagnostics

#### Genome analysis service supply contract signed with a major hospital partner in Mongolia (June 12, 2024) ▼

On June 12, 2024, our company signed a contract to supply genome analysis services with Regenerative Cell Center LLC (RCC), a major hospital partner in Mongolia. RCC is a biomedical company that partners with the Mongolian fertility and reproductive clinic center, RMC IVF Center, providing genome analysis services such as Non-Invasive Prenatal Testing (NIPT) and Preimplantation Genetic Testing (PGT), as well as local marketing. The partner fertility center in Mongolia specializes in treating infertility patients and leads the domestic promotion of genome analysis services.

With an increasing trend of pregnancies in women over 35 in Mongolia, there is growing awareness of the importance of genome analysis services for the health management of mothers and fetuses. The Dx&Vx genome analysis service, recognized for its technical prowess and safety by local medical professionals, marks a significant step in expanding our reach into the global market with this supply contract in Mongolia.

#### Launching 'Omic-Check Microbiome Healthcare Service' (June 26, 2024) ▼

The "Omic-Check Microbiome Healthcare Service" targets all age groups from newborns to adults, providing insights into the distribution and characteristics of microbiome microbes in the gut, oral cavity, and skin. Our service is set to become a foundation for personalized bio-healthcare, as it includes genome analysis and offers probiotics tailored to individual growth processes due to each person's unique beneficial bacteria.

Building on our core competencies in the medical diagnostics sector, we plan to expand our bio-healthcare services by integrating microbiome analysis for health management, personalized product development, and production technologies and know-how developed by our affiliated company, Coree Group, in the global market. Additionally, leveraging the largest domestic prenatal and postnatal clinical genomic big data, we aim to develop personalized microbiome treatments (new drug development) for chronic diseases, genetic disorders, infections, and various cancers.

#### Genome analysis service supply contract signed with a Malaysian bio-healthcare company (June 27, 2024) ▼

On June 27, 2024, we entered into a supply contract with Malaysia's MGRC Therapeutics to provide local services for Dx&Vx's genome analysis service, "GenomeCheck." Founded in 2010, MGRC is a bio-healthcare company listed on the Bursa Malaysia. Through MGRC's extensive network, the "GenomeCheck" service will be supplied to local clinics and hospitals in Malaysia.

This agreement marks our initial step into the Southeast Asian market, including Malaysia, and we plan to discuss various cooperation strategies in other business areas such as in vitro diagnostics and digital healthcare to expand our service offerings. Building on our earlier market entry into Mongolia, venturing into the Southeast Asian market signifies a significant move from the limited domestic genome analysis market to broadening our sales diversification and increase through global market expansion.



## Consumer Healthcare

### \$4 Million Export Contract for 'Ofmom' Brand in Vietnam (June 24, 2024) ▼

On June 24, 2024, our company signed a \$4 million export supply contract (approximately 5.6 billion KRW, representing 12% of last year's revenue) with Vietnam's Ofmeight. The products to be produced and supplied under this contract include items from the Ofmom brand Mate series, as well as women's health and beauty probiotic products. Ofmeight, our trading partner, is a local Vietnamese corporation specializing in the direct distribution and sale of health and beauty products through both online and offline channels.

This export contract to Vietnam marks the beginning of expanding our distribution network from primarily Korea and China into the Southeast Asian market. Additionally, discussions are underway to further supply agreements with several specialized health and beauty distributors in the USA, Japan, and other countries. In the second half of this year, we anticipate further exploring international markets, aiming to position our Ofmom and Dx&Vx brands as global healthcare leaders, with 30% of our 2024 consumer healthcare sales projected to come from international markets.



## Drug Development

### Excellent preclinical trial results confirmed for oral obesity treatment candidate (June 14, 2024) ▼

Our oral glucagon-like peptide GLP-1RA (Receptor Agonist) obesity treatment candidate has demonstrated excellent efficacy in preclinical stages. This next-generation oral obesity treatment offers patients a new therapeutic option through its convenient dosing method, exceptional efficacy, and safety, potentially stimulating growth in the obesity treatment market. We anticipate minimal side effects while maintaining a similar mechanism of action to existing injectable GLP-1 peptide-based obesity treatments.

Utilizing our proprietary AI technology, we have quickly synthesized multiple new drug candidates with fewer compounds, confirming superior efficacy compared to competing drugs in this preclinical trial. We plan to accelerate development by identifying the optimal candidate through further preclinical tests on safety and efficacy, aiming to finalize by the end of this year.

## Compliance Notice

This document is prepared solely for informational purposes to assist investors' understanding. It is based on data and information considered reliable, and has been diligently compiled; however, we do not guarantee its accuracy or completeness. Investment decisions should be made based on the investor's own judgment and responsibility. Under no circumstances can this material be used as legal evidence of liability for investment results.